Adipositas - Ursachen, Folgeerkrankungen, Therapie 2021; 15(03): 150
DOI: 10.1055/s-0041-1735670
Abstracts
Wiesbaden: Adipositas-Kongress 2021

5 Weight-Loss Maintenance with Once-Weekly Semaglutide 2.4 mg in Adults with Overweight or Obesity Reaching Maintenance Dose (STEP 4)

Domenica Rubino
1   Washington Center for Weight Management, Arlington, USA
,
Niclas Abrahamsson
2   Uppsala University, Uppsala, Schweden
,
Melanie Davies
3   University of Leicester, Leicester, Vereinigtes Königreich
,
Dan Hesse
4   Novo Nordisk, Soborg, Dänemark
,
Frank Greenway
5   Louisiana State University System, Baton Rouge, USA
,
Camilla Jensen
4   Novo Nordisk, Soborg, Dänemark
,
Ildiko Lingvay
6   Southwestern Medical Center, Dallas, USA
,
Tanja Wiedenmann
7   Novo Nordisk, Mainz, Deutschland
,
Ofri Mosenzon
8   Hebrew University of Jerusalem, Jerusalem, Israel
,
Julio Rosenstock
9   Dallas Diabetes Research Center at Medical City, Dallas, USA
,
Miguel Rubio
10   Hospital Clínico Universitario San Carlos and Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spanien
,
Gottfried Rudolfsky
11   Cantonal Hospital, Olten, Schweiz
,
Sayeh Tadayon
4   Novo Nordisk, Soborg, Dänemark
,
Thomas Wadden
12   University of Pennsylvania, Philadelphia, USA
,
Dror Dicker
13   Tel Aviv University, Tel Aviv, Israel
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
 

Zusammenfassung

In adults with overweight or obesity, continued treatment with OW s.c. semaglutide 2.4 mg led to clinically relevant weight loss, while switching to placebo led to significant weight regain; these data underscore the chronicity and relapsing nature of obesity, and the need for continued treatment.



Publikationsverlauf

Artikel online veröffentlicht:
24. September 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany